Orbital decompression following treatment with teprotumumab for thyroid eye disease.

Can J Ophthalmol

Division of Oculofacial Plastic and Reconstructive Surgery, University of California San Diego Viterbi Family Department of Ophthalmology, Shiley Eye Institute, La Jolla, CA; Division of Plastic Surgery, Department of Surgery, University of California San Diego Department of Surgery, La Jolla, CA.

Published: February 2025

Objective: To quantify the observed decrease in orbital decompressions being performed at one tertiary care institution and to determine the rate and predictive factors of orbital decompression surgery following treatment with teprotumumab for thyroid eye disease.

Methods: Epic's SlicerDicer program was used to analyze recent trends in the overall number of thyroid eye disease (TED) patients evaluated in the oculoplastic surgery department, as well as usage trends of CPT codes 67445 (lateral orbitotomy with bone removal for decompression) and 67414 (orbitotomy with removal of bone for decompression). A retrospective chart review of active moderate-to-severe TED patients treated with teprotumumab was performed at a single tertiary care center. The main outcome measure was whether or not patients underwent bony orbital decompression surgery following treatment with teprotumumab. The SlicerDicer search demonstrated stable usage of CPT codes 67445 and 67414 from 2016 to 2019, followed by a significant decrease from 2020 to 2023, over a background of increasing numbers of TED patients evaluated in clinic. Following teprotumumab therapy, 25% of patients and 18% of orbits underwent bony decompression. Surgically decompressed patients had higher pre- and post-teprotumumab exophthalmometry measurements compared with patients who did not undergo bony decompression. Average time to decompression following conclusion or cessation of teprotumumab therapy was 12.6 months.

Conclusion: While the number of TED patients treated at one tertiary care center has risen over recent years, the number of orbital decompression surgeries has declined. Orbital decompression, however, is still needed in select patients after treatment with teprotumumab.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcjo.2024.06.003DOI Listing

Publication Analysis

Top Keywords

orbital decompression
20
treatment teprotumumab
16
ted patients
16
thyroid eye
12
tertiary care
12
decompression
9
patients
9
teprotumumab thyroid
8
eye disease
8
decompression surgery
8

Similar Publications

A 21-year-old woman presented with progressive proptosis of the right eye with blurring of vision for the past 6 months. MRI showed an intra-orbital lesion that was T1 isointense, T2 hyperintense, and well enhancing on contrast. The patient underwent right frontal craniotomy, superior orbitotomy, and decompression of the lesion.

View Article and Find Full Text PDF

A 73-year-old male with a history of incidentally diagnosed Paget disease of bone affecting the skull and left orbit 2 years prior presented with 3 months of vision loss, proptosis, and periorbital swelling of the OS. Examination showed best-corrected Snellen visual acuity of 20/150 in the affected eye, intact motility, 7 mm of relative proptosis, significant dilated and tortuous "corkscrew" conjunctival vessels, serous choroidal and retinal detachments, optic nerve hyperemia, and venous tortuosity and dilation. Although the bony lesions in the left orbit were stable from 1 year prior on imaging, the diagnostic angiogram demonstrated osseous blush and hypervascularity of the lesion.

View Article and Find Full Text PDF

Traumatic optic neuropathy (TON) is a rare condition resulting from damage to the optic nerve due to craniofacial trauma. It can present as direct or indirect injuries, with mechanisms ranging from mechanical disruption by fractures in direct TON to transmitted forces causing shearing and ischemia in indirect TON. These injuries often lead to significant visual impairment or complete vision loss, requiring timely diagnosis and intervention.

View Article and Find Full Text PDF

Background: To report the presenting clinical, serological and treatment profiles of 1439 patients with thyroid eye disease (TED) from a tertiary centre in Hong Kong.

Study Populations: Consecutive patients with TED presented to the Thyroid Eye Clinic (TEC), the Chinese University of Hong Kong between 2014 and 2023.

Methods: Prospective cohort and masked review of medical records and orbital images.

View Article and Find Full Text PDF

Atypical lacrimal sac mucoceles.

Orbit

January 2025

Govindram Seksaria Institute of Dacryology, L.V. Prasad Eye Institute, Hyderabad, India.

Purpose: To report the clinical features and operative findings of a series of patients with lacrimal sac mucoceles extending above the anatomic level of the medial canthal tendon (MCT).

Methods: A retrospective chart review of all patients presenting with lacrimal sac mucocele extending above the anatomic level of the MCT over a period of five years from 2019 and 2023. All patients underwent surgical management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!